Crescent Capital BDC (NASDAQ:CCAP – Get Free Report) and Advanced Medical Isotope (OTCMKTS:RDGL – Get Free Report) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.
Analyst Ratings
This is a summary of recent ratings and target prices for Crescent Capital BDC and Advanced Medical Isotope, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Crescent Capital BDC | 0 | 3 | 3 | 1 | 2.71 |
| Advanced Medical Isotope | 0 | 0 | 0 | 0 | 0.00 |
Crescent Capital BDC presently has a consensus price target of $15.60, indicating a potential upside of 28.40%. Given Crescent Capital BDC’s stronger consensus rating and higher probable upside, analysts clearly believe Crescent Capital BDC is more favorable than Advanced Medical Isotope.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Crescent Capital BDC | $167.29 million | 2.68 | $34.51 million | $0.94 | 12.93 |
| Advanced Medical Isotope | $30,000.00 | 1,446.46 | -$2.91 million | N/A | N/A |
Crescent Capital BDC has higher revenue and earnings than Advanced Medical Isotope.
Profitability
This table compares Crescent Capital BDC and Advanced Medical Isotope’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Crescent Capital BDC | 20.64% | 9.32% | 4.07% |
| Advanced Medical Isotope | -6,144.90% | N/A | -113.56% |
Institutional & Insider Ownership
49.5% of Crescent Capital BDC shares are owned by institutional investors. 1.1% of Crescent Capital BDC shares are owned by insiders. Comparatively, 18.5% of Advanced Medical Isotope shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Crescent Capital BDC has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Advanced Medical Isotope has a beta of -0.64, meaning that its share price is 164% less volatile than the S&P 500.
Summary
Crescent Capital BDC beats Advanced Medical Isotope on 11 of the 13 factors compared between the two stocks.
About Crescent Capital BDC
Crescent Capital BDC, Inc. is as a business development company private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.
About Advanced Medical Isotope
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.
Receive News & Ratings for Crescent Capital BDC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescent Capital BDC and related companies with MarketBeat.com's FREE daily email newsletter.
